Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.17 USD
Change Today -0.03 / -2.50%
Volume 9.3K
SKBI On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

skystar bio-pharmaceutical (SKBI) Snapshot

Open
$1.20
Previous Close
$1.20
Day High
$1.20
Day Low
$1.12
52 Week High
09/9/14 - $5.92
52 Week Low
08/26/15 - $1.03
Market Cap
10.2M
Average Volume 10 Days
14.8K
EPS TTM
$1.33
Shares Outstanding
8.7M
EX-Date
--
P/E TM
0.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for SKYSTAR BIO-PHARMACEUTICAL (SKBI)

Related News

No related news articles were found.

skystar bio-pharmaceutical (SKBI) Related Businessweek News

No Related Businessweek News Found

skystar bio-pharmaceutical (SKBI) Details

Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People’s Republic of China. The company offers micro-organism products, veterinary medicines for poultry and livestock, feed additives, and bio-pharmaceutical veterinary vaccines. It markets its products through distributers and franchise distributors, as well as directly to customers. The company is headquartered in Xi’an, the People’s Republic of China.

skystar bio-pharmaceutical (SKBI) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $121.6K
Chief Financial Officer
Total Annual Compensation: $182.5K
Compensation as of Fiscal Year 2013.

skystar bio-pharmaceutical (SKBI) Key Developments

Skystar Bio-Pharmaceutical Company Announces Receipt Of Nasdaq Non-Compliance Letter Due To Delay In Filing Form 10-Q

Skystar Bio-Pharmaceutical Company announced that on August 19, 2015, the Company received a notification from the Nasdaq Stock Market ("Nasdaq") informing the Company that because it had not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Company previously submitted a plan of compliance to Nasdaq, responded to an initial request for additional information from Nasdaq, and is preparing responses to a second request for additional information from Nasdaq. If its plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days from the date of its initial delinquent filing (its Annual Report on Form 10-K for the year ended December 31, 2014), or until October 12, 2015, to regain compliance. The Nasdaq notification letters do not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under its current trading symbol. If the Nasdaq staff concludes that the Company will not be able to cure the deficiency, or if the Company determines not to submit the required materials or make the required representations, the Company's common stock will be subject to delisting by Nasdaq.

Skystar Bio Pharmaceutical Company announced delayed 10-Q filing

On 08/14/2015, Skystar Bio Pharmaceutical Company announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Skystar Bio-Pharmaceutical Company Announces Submission Of Plan Of Compliance With Nasdaq

Skystar Bio-Pharmaceutical Company announced that the Company timely submitted a "Plan of Compliance" to Nasdaq in accordance with applicable Nasdaq rules. The Plan of Compliance sets out the Company's plan to regain compliance with Nasdaq's continued listing rules. On April 15, 2015, and May 22, 2015, the Company received notifications from the Nasdaq Stock Market ("Nasdaq") informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and its Quarterly Report on Form 10-Qfor the quarter ended March 31, 2015, respectively, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letters do not result in the immediate delisting of the Company's common stock, and the stock has continued to trade under its current trading symbol. If the Plan of Compliance is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days from the original notice of non-compliance, or until October 12, 2015, to regain compliance. If the Nasdaq staff concludes that the Company will not be able to cure the deficiency, the Company's common stock will be subject to delisting by Nasdaq. Skystar intends to regain compliance and report full year fiscal 2014 results and first quarter fiscal 2015 results as soon as practicable.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKBI:US $1.17 USD -0.03

SKBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China Animal Husbandry Industry Co Ltd CNY21.17 CNY +1.66
Inner Mongolia Jinyu Group Co Ltd CNY51.90 CNY +4.34
Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd CNY8.90 CNY +0.74
View Industry Companies
 

Industry Analysis

SKBI

Industry Average

Valuation SKBI Industry Range
Price/Earnings 0.9x
Price/Sales 0.2x
Price/Book 0.1x
Price/Cash Flow 0.9x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYSTAR BIO-PHARMACEUTICAL, please visit www.skystarbio-pharmaceutical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.